GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients — Stella

Home/Endometrial Neoplasms/

View on ClinicalTrials.gov

Recruiting

Back to Endometrial Neoplasms trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Tenth People's Hospital of Tongji University, Shanghai, Shanghai Municipality

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Xiaojun Chen

Enrollment target

~29 participants

Started

July 2022

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

Sex

Female only

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.